{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
sulfisoxazole acetyl
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Cebaracetam is piperazinylpyrrolidinone derivative patented by pharmaceutical company Ciba-Geigy A.-G. for treatment of amnesia and retention defects.
Class (Stereo):
CHEMICAL (RACEMIC)
Etacepride is a neuroleptic and antiemetic agent.
Status:
Investigational
Source:
NCT00690638: Phase 3 Interventional Completed Type 2 Diabetes Mellitus
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dutogliptin (PHX-1149T) is a small-molecule dipeptidyl peptidase-4 (DPP-4) inhibitor for the potential oral treatment of type 2 diabetes mellitus (T2DM). DPP-4 quickly degrades the insulin secretory hormones, glucose-dependent insulinotropic peptide and glucagon-like peptide-1; thus inhibiting the degradation of these hormones is a viable treatment option for patients with T2DM. In preclinical studies, dutogliptin potently inhibited DPP-4 and, in a model of T2DM, treatment with dutogliptin improved glucose homeostasis. Pharmacokinetic analyses in animals, healthy individuals and patients with T2DM demonstrated that drug exposure increased in a dose-dependent manner. Results from phase II clinical trials indicated that once-daily dutogliptin, in combination with other oral diabetes therapies, reduces postprandial blood glucose and HbA1c levels, both indicators of successful diabetes management. The incidence of adverse events was similar in treatment and placebo groups, with slightly more headache, arthralgia, sinusitis, and dizziness occurring in the 400 mg dutogliptin group compared with placebo. Phase II clinical trial for the myocardial infarction treatment is underway.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cinaproxen is naproxen derivative developed by Nicox S.A. for oxidative stress prevention and treatment.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cefuracetime is an impurity of Cefuroxime, which is an antibacterial agent.
Status:
Investigational
Source:
INN:diphoxazide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Diphoxazide is the anticonvulsant and psychosedative agent.
Class (Stereo):
CHEMICAL (RACEMIC)
Loviride (R 89439) is a non-nucleoside inhibitor of reverse transcriptase. It inhibits virion and recombinant reverse transcriptase of HIV-1. It was being studied in the combination therapy of HIV infection with other anti-HIV agents.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Salnacedin (also known as G 201) was developed as a topical anti-inflammatory agent; Salnacedin participated in phase II clinical trials in the USA for the treatment of dermatitis, acne, and psoriasis. However, all these studies were discontinued.
Status:
Investigational
Source:
Sci Rep. Sep 2019;9(1):12760.: Phase 3 Human clinical trial Completed Breast Neoplasms/metabolism/mortality
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Maytansine is an ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata. Maytansine inhibits the assembly of microtubules by binding to tubulin at or near the vinblastine-binding site, decreases microtubule dynamic instability and cause mitotic arrest in cells. It exerts cytotoxicity against a number of tumor cell lines and inhibits tumor growth in vivo. However, in human clinical trials, maytansine showed a small therapeutic window due to its neurotoxicity and harmful effects on the gastrointestinal tract. The potent cell killing ability of maytansine can be used in a targeted delivery approach, such as an antibody-drug conjugate, for the selective delivery of the drug and destruction of cancer cells.
Class (Stereo):
CHEMICAL (ABSOLUTE)
LADIRUBICIN is an idarubicin derivative with potential antineoplastic activity. Its primary effect is a DNA alkylation with sequence specificity similar to that of conventional nitrogen mustards. It possesses a wide spectrum antitumor activity against rapidly proliferating murine leukemias and on slowly growing transplantable human tumor xenografts.
